5 days ago
1
Grandbrothers/iStock Editorial via Getty Images
Agios Pharmaceuticals (NASDAQ:AGIO) fell ~17% in the premarket on Thursday after the U.S. FDA issued a three-month extension to the review period for the company’s lead asset, Pyrukynd, targeted at alpha- or beta-thalassemia.
Earlier this year, the agency granted September 7, 2025, as
English (US) ·